Hong Kong stocks surged, with the Hang Seng Index closing up 1.43%; biomedical stocks rallied significantly in the late trading session, with Wuxi Apptec up nearly 12%.
The three main stock indexes in Hong Kong surged in the morning, with a significant increase, and the gains slightly narrowed in the afternoon but overall remained strong. At the close, the Hang Seng Index and the H-share Index rose by more than 1%, while the hang seng tech index increased by 1.43%, surging to 2.5% at one point during the day. All three major indexes continued their upward trend, setting new highs in the recent rebound.
Express News | Hong Kong stock CRO concept stocks soared at the close, what happened?
BeiGene Executive Wu Xiaobin Sells Over $1 Million in Company Stock
BeiGene Initiated at Outperform at JMP Securities on Strength of Brukinsa
JMP Securities Initiates Coverage On BeiGene With Market Outperform Rating, Announces Price Target of $288
BeiGene Analyst Ratings
BeiGene's TEVIMBRA Gains Approval for OSCC in Israel
JMP Securities Initiates BeiGene(BGNE.US) With Buy Rating, Announces Target Price $288
JMP Securities analyst Reni Benjamin initiates coverage on $BeiGene(BGNE.US)$ with a buy rating, and sets the target price at $288.According to TipRanks data, the analyst has a success rate of 32.4%
Reni Benjamin Endorses BeiGene With a Buy Rating Amidst Strong Financial Outlook and Market Penetration
BeiGene Says Israeli Ministry Of Health Approved TEVIMBRA (Tislelizumab) As Monotherapy For Treatment Of Adult Patients With Unresectable Or Metastatic OESCC After Prior Systemic Chemotherapy
BeiGene Receives Israeli Ministry of Health Approval for TEVIMBRA for the Treatment of Oesophageal Squamous Cell Carcinoma (OSCC) After Prior Chemotherapy
Hong Kong stocks turned around in the afternoon! Both Hang Seng Index and Technology Index reversed and rose, what happened?
Analysts believe that, under the current circumstances, both the Hong Kong stock market and the A-share market need policies as triggers. If China's stimulus policies can timely follow and exceed expectations after the Fed rate cut, the market may usher in a wave of prosperity.
US stock preview | Earnings guidance exceeds expectations! Oracle continues to rise more than 6% pre-market; Is the US stock correction over? Deutsche Bank: Three major bullish factors may support new highs in US stocks.
The Q4 revenue outlook does not highlight the profitability improvement of AI, and Adobe's pre-market plunge exceeds 8%; Fitch: The Fed's rate cut should be gradual rather than hasty, and is expected to make a moderate 250 basis point rate cut over the next two years; Will the Fed's rate cut signal be sounded? Goldman Sachs executives highly recommend small-cap stock hunting.
Beigene's stock rose nearly 2% pre-market as the National Medical Products Administration accelerated the approval of clinical pharmaceuticals.
On September 13th, Beigene (BGNE.US) rose 1.9% pre-market to $200. The State Council Information Office held a series of themed press conferences on "Promoting High-Quality Development" today. Li Li, the director of the National Medical Products Administration, introduced that the NMPA is accelerating the evaluation and approval of urgently needed clinical products, and will include eligible products in the priority evaluation and approval process. The time limit for the evaluation and approval of innovative drug clinical trials will be shortened from 60 working days to 30 working days.
Hong Kong pharmaceutical stocks continue to rise! The National Medical Products Administration accelerates the approval of clinical drugs, institutions are bullish on the rapid development of innovative drugs.
Soochow Securities has released a research report stating that the development of domestic new drugs in various stages of clinical trials and the participation of domestic new drugs in international multicenter clinical trials reflect a significant enhancement of China's research and development capabilities.
BeiGene Singapore Raises Awareness for World Lymphoma Awareness Day 2024: It's Time for Honest Talk
New Additions to Roth MKM's ADR Portfolio for September
US stocks outlook: August PPI slightly lower than expected, three major futures indexes slightly lower; downgraded by major banks! Micron Technology pre-market fell more than 3%
Goldman Sachs CEO: There are signs of weakness in the job market, and the Fed may still cut interest rates by 50 basis points. UBS Group CEO: The market's expectation for a rate cut by the Fed is too aggressive, bullish on a soft landing for the US economy. Nvidia soared 8% overnight and saved the US stock market! Multiple call options made 10 times the profit.
Oxford Industries Reports Weak Results, Joins Viper Energy And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Beigene responds to AbbVie's lawsuit accusing it of stealing trade secrets: intending to obstruct the development process.
Beigene stated that the development of the BGB-16673 project will not be interrupted by this lawsuit.